文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

免疫检查点蛋白 VISTA 通过调节髓系细胞介导的炎症和免疫抑制来调控抗肿瘤免疫。

Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.

机构信息

Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin.

Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, Ohio.

出版信息

Cancer Immunol Res. 2019 Sep;7(9):1497-1510. doi: 10.1158/2326-6066.CIR-18-0489. Epub 2019 Jul 24.


DOI:10.1158/2326-6066.CIR-18-0489
PMID:31340983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6726548/
Abstract

Immune-checkpoint protein V-domain immunoglobulin suppressor of T-cell activation (VISTA) controls antitumor immunity and is a valuable target for cancer immunotherapy. This study identified a role of VISTA in regulating Toll-like receptor (TLR) signaling in myeloid cells and controlling myeloid cell-mediated inflammation and immunosuppression. VISTA modulated the polyubiquitination and protein expression of TRAF6. Consequently, VISTA dampened TLR-mediated activation of MAPK/AP-1 and IKK/NF-κB signaling cascades. At cellular levels, VISTA regulated the effector functions of myeloid-derived suppressor cells and tolerogenic dendritic cell (DC) subsets. Blocking VISTA augmented their ability to produce proinflammatory mediators and diminished their T cell-suppressive functions. These myeloid cell-dependent effects resulted in a stimulatory tumor microenvironment that promoted T-cell infiltration and activation. We conclude that VISTA is a critical myeloid cell-intrinsic immune-checkpoint protein and that the reprogramming of tolerogenic myeloid cells following VISTA blockade promotes the development of T cell-mediated antitumor immunity.

摘要

免疫检查点蛋白 V 结构域免疫球蛋白抑制 T 细胞激活(VISTA)控制抗肿瘤免疫,是癌症免疫治疗的有价值的靶点。本研究确定了 VISTA 在调节髓样细胞中的 Toll 样受体(TLR)信号以及控制髓样细胞介导的炎症和免疫抑制中的作用。VISTA 调节 TRAF6 的多泛素化和蛋白表达。因此,VISTA 抑制 TLR 介导的 MAPK/AP-1 和 IKK/NF-κB 信号级联的激活。在细胞水平上,VISTA 调节髓系来源的抑制细胞和耐受性树突状细胞(DC)亚群的效应功能。阻断 VISTA 增强了它们产生促炎介质的能力,并降低了它们的 T 细胞抑制功能。这些依赖于髓样细胞的效应导致刺激肿瘤微环境,促进 T 细胞浸润和激活。我们得出结论,VISTA 是一种关键的髓系细胞内在免疫检查点蛋白,VISTA 阻断后耐受性髓样细胞的重编程促进了 T 细胞介导的抗肿瘤免疫的发展。

相似文献

[1]
Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.

Cancer Immunol Res. 2019-7-24

[2]
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Cancer Immunol Res. 2019-5-14

[3]
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity.

J Immunother Cancer. 2024-8-28

[4]
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.

Front Immunol. 2018-6-4

[5]
Expression and function of VISTA on myeloid cells.

Biochem Pharmacol. 2024-4

[6]
VISTA Re-programs Macrophage Biology Through the Combined Regulation of Tolerance and Anti-inflammatory Pathways.

Front Immunol. 2020-10-15

[7]
VISTA Regulates the Development of Protective Antitumor Immunity.

Cancer Res. 2014-4-1

[8]
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation.

J Mol Med (Berl). 2020-10

[9]
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

J Immunol. 2018-1-15

[10]
The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.

Front Immunol. 2020

引用本文的文献

[1]
Macrophage-derived VISTA engages with LRIG1 and hinders gut epithelial repair in colitis.

Cell Mol Immunol. 2025-8-29

[2]
Target neutrophil heterogeneity and plasticity in cancer.

J Hematol Oncol. 2025-8-12

[3]
Emerging IO checkpoints in gastrointestinal oncology.

Front Immunol. 2025-7-24

[4]
Development and validation of a hypoxia-immune-based microenvironment gene signature for predicting survival in non-small cell lung cancer.

Discov Oncol. 2025-8-4

[5]
The role of VISTA engagement in limiting neutrophil-mediated inflammation.

J Immunol. 2025-6-26

[6]
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade.

Front Immunol. 2025-5-9

[7]
Therapeutic targeting of tumour-associated macrophage receptors.

Immunother Adv. 2025-3-11

[8]
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families.

Front Immunol. 2025-4-28

[9]
Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.

Exp Hematol Oncol. 2025-5-2

[10]
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy.

Naunyn Schmiedebergs Arch Pharmacol. 2025-4-11

本文引用的文献

[1]
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.

Front Immunol. 2018-6-11

[2]
The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Cell Mol Immunol. 2018-1-29

[3]
Myeloid-derived suppressor cells coming of age.

Nat Immunol. 2018-1-18

[4]
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.

Cancer Cell. 2014-12-8

[5]
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Cancer Cell. 2017-5-8

[6]
Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.

Sci Rep. 2017-5-3

[7]
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Cell Rep. 2017-4-4

[8]
Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Cancer Res. 2017-5-15

[9]
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Nat Med. 2017-5

[10]
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Science. 2017-3-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索